Inhibiting the TLR4-RIPK3-mediated necroptotic pathway, which is activated by bacterial infection, can effectively reduce the release of DAMPs, thereby mitigating immune imbalance and dampening the amplification of inflammation. Here, RIPK3 is linked to bacterial infectious disease.